Datopotamab Deruxtecan, often abbreviated as DATO, represents the important advancement within targeted cancer therapy. This new antibody-drug conjugate joins an monoclonal immunoglobulin specifically directed at HER2 https://www.targetmol.com/compound/datopotamab